Evaluation of synthetic substituted 1,2-dioxanes as novel agents against human leishmaniasis by Ortalli M. et al.
lable at ScienceDirect
European Journal of Medicinal Chemistry 170 (2019) 126e140Contents lists avaiEuropean Journal of Medicinal Chemistry
journal homepage: http: / /www.elsevier .com/locate/ejmechResearch paperEvaluation of synthetic substituted 1,2-dioxanes as novel agents
against human leishmaniasis
M. Ortalli a, 1, S. Varani a, b, 1, C. Rosso c, A. Quintavalla c, *, M. Lombardo c, C. Trombini c, **
a Alma Mater Studiorum - University of Bologna, Department of Experimental, Diagnostic and Specialty Medicine, Via Massarenti 9, 40138, Bologna, Italy
b Unit of Clinical Microbiology, Regional Reference Centre for Microbiological Emergencies (CRREM), St. Orsola-Malpighi University Hospital, Via Massarenti
9, 40138, Bologna, Italy
c Alma Mater Studiorum - University of Bologna, Department of Chemistry “G. Ciamician”, Via Selmi 2, 40126, Bologna, Italya r t i c l e i n f o
Article history:
Received 22 November 2018
Received in revised form
29 January 2019
Accepted 25 February 2019





Neglected tropical disease* Corresponding author.
** Corresponding author.
E-mail address: arianna.quintavalla@unibo.it (A. Q
1 These authors equally contributed to this work.
https://doi.org/10.1016/j.ejmech.2019.02.070
0223-5234/© 2019 The Authors. Published by Elsevier
nd/4.0/).a b s t r a c t
The treatment of human leishmaniasis is currently based on few compounds that are highly toxic,
expensive and have a high rate of treatment failure. A number of recent studies on new drugs focuses on
natural or semi-synthetic compounds. Among them, the endoperoxide artemisinin, extracted from
Artemisia annua, and some of its derivatives have shown leishmanicidal activity. In the present work, a
series of structurally simple, fully synthetic 1,2-dioxanes were evaluated for in vitro antileishmanial
activity against promastigotes of Leishmania donovani; the cytotoxicity for mammalian cells was also
assessed. The six most promising compounds in terms of activity and selectivity were further investi-
gated for their antileishmanial activity on the promastigote forms of L. tropica, L. major and L. infantum
and against L. donovani amastigotes. The good performance in terms of potency and selectivity makes
these six hits promising candidates for a preliminary lead optimization as antileishmanial agents.
© 2019 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human leishmaniasis is one of the most burdensome neglected
tropical diseases, which is endemic in around 100 countries
including Southern Europe, Asia, Africa, and Latin America, with
more than 350million people living at risk of developing one of the
many forms of the disease [1]. Leishmania parasites are transmitted
into mammalian host by the bite of phlebotomine sand flies (genus
Phlebotomus in the Old World and Lutzomyia in the New World) as
promastigotes (flagellates), that transform into aflagellated amas-
tigotes in host macrophages [2]. Leishmaniasis is considered a
neglected tropical disease and it is linked to poverty, but environ-
mental and climate-related factors also influence the disease's
epidemiology. In the last decades, probably due to global warming,
long-distance tourism and trade, leishmaniasis has spread to
countries, including industrialized countries, previously considered
unsuitable for the proliferation of the vector and/or the parasite
[3,4]. The clinical spectrum of human infection ranges from the life-uintavalla).
Masson SAS. This is an open accessthreatening visceral disease (VL) characterized by fever, spleno-
megaly, pancytopenia and weight loss, to disfiguring mucosal (ML)
and cutaneous (CL) forms, to asymptomatic infection [5].
The currently employed pharmacological approach to treat
leishmaniases is based on few drugs including pentavalent antimo-
nials (meglumine antimoniate and sodium stibogluconate), lip-
osomial amphotericin B, paromomycin, miltefosine, pentamidine
and sitamaquine (Fig. 1) [6]. Treatments are unsatisfactory in terms
of safety and efficacy, which sharply contrasts with the therapeutic
need in terms of people at risk, number of affected patients and
associated fatalities. Indeed, many different toxic effects and adverse
reactions are associated with the use of the currently employed
drugs [6,7] and drug resistance is nowadays a serious problem in
some endemic areas [8]. The recently introduced compounds and
formulations display good efficacy, but the high costs and/or the low
bioavailability limit in some cases their application [9].
Nowadays, leishmaniasis is still lacking an effective, safe, and
affordable chemotherapy.
The several drawbacks shown by antileishmanial drugs,
together with the worldwide high impact of leishmaniasis on the
public health, prompt the scientific community to urgently identify
new chemical entities able to act as effective, safe and cheap anti-
leishmanial drugs [10,11].article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
 
Fig. 1. Drugs currently employed for the treatment of leishmaniases (the reported IC50 values concern bioassays on promastigotes of Leishmania donovani strains).
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are exhibited by plant-derived substances. In this context, the
endoperoxide artemisinin and its derivatives (Fig. 2) play a crucial
role, owning to a wide range of biological activities [12]. Artemisinin
and some semi-synthetic derivatives, such as dihydroartemisinin or
artesunate (Fig. 2), are the main components of artemisinin-based
combination therapies (ACTs), recommended by the World Health
Organization (WHO) as first-line treatment for Plasmodium falcipa-
rum malaria in disease-endemic countries [13]. In addition,
artemisinin-based compounds revealed to be active as antimicrobial
[14] and antiviral agents [15]. Furthermore, artemisinin derivatives
display bioactivity also against non-malarial protozoa that infect
humans, such as Leishmania spp. and Trypanosoma spp [12].
Concerning the Leishmania treatment, one of the most relevant
features of the artemisinin-derived endoperoxides is the ability toinhibit the parasite metabolism with limited adverse effects on the
host cells [16]. Studies were carried out on the activity of artemi-
sinin derivatives on Leishmania (Fig. 2), with varying IC50 values
depending on the compound structure, the tested parasite species
and the selected parasite form (promastigote or amastigote) (Fig. 2)
[12,17].
It is noteworthy that the in vitro efficacy of some of these semi-
synthetic cyclic peroxides is comparable to or, in some cases,
higher than those of amphotericin B, miltefosine, and sitamaquine
[12].
Among the endoperoxide-based scaffolds tested against Leish-
mania spp., the fully synthetic and structurally simple trioxolanes
LC50 and LC95 (Fig. 2) display good bioactivity profiles when tested
in vitro against promastigotes (IC50 range 3.51 mMe9.35 mM) and a
modest activity against intracellular amastigotes (IC50 range
Fig. 2. Antileishmanial activity of some artemisinin derivatives and synthetic trioxolanes (the reported IC50 values concern bioassays on promastigotes of L. donovani for artemisinin
derivatives and of L. infantum for trioxolanes).
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thetic trioxolanes are more effective than dihydroartemisinin and
artesunate, and show higher selectivity index (SI) values than those
of commercially available antileishmanial drugs.
In the last years, part of our ongoing research work was focused
on the design and synthesis of new antimalarial agents [19]. In
details, we proposed an efficient and cheap synthetic strategy to
assemble simple 3-methoxy-1,2-dioxanes 8 suitably decorated in
position 4 and 6 (Scheme 1). Inspired by the good antileishmanial
properties shown by some endoperoxide-containing scaffolds, such
as artemisinin derivatives and trioxolanes (Fig. 2), we decided to
test our 1,2-dioxanes library for antileishmanial activity and to
design new and specifically substituted endoperoxides that could
be able to act as antileishmanial compounds.
The objectives of the present study are: i) the development of
an efficient protocol to synthesize new antileishmanial 1,2-
dioxanes; ii) a preliminary investigation of the structure-activity
relationships (SARs), iii) the identification of a possible pharma-
cophore model. The structural simplicity of the proposed 1,2-
dioxanes and the ease of synthesis at low cost represent a major
advantage over natural compounds, which are characterized by
complex structures that are only marginally modifiable. Indeed,
we are able to obtain a family of variously substituted compounds,
which allows us to identify the crucial pharmacophore molecular
portions. In the long run we will focus our efforts to unravel the
mechanism of action and the biological target of this family of
anti-parasitic compounds.2. Results and discussion
2.1. Synthesis of the first series of endoperoxides and in vitro
inhibition of L. donovani promastigotes growth
A small library of 3-methoxy-1,2-dioxanes has been prepared
through an efficient (up to 59% overall yield) and low cost synthetic
approach developed in our lab [19]. The optimized protocol consists
of five steps based on a key formal [2þ2þ2] free radical cycload-
dition of a b-ketoester (1), a gem-disubstituted alkene (2) and
molecular oxygen, promoted by catalytic amounts of manganese
salts (Scheme 1). The obtained hemiketal (3) was first converted
into the methylketal (4) and then reduced to the corresponding
alcohol (5). Finally, an oxidation to aldehyde (6) followed by a
reductive amination led to the desired substituted endoperoxide
(8). The flexibility of the synthetic strategy enables the construction
of several endoperoxides variously functionalized on the 3, 4 and 6
positions by simply varying the nature of the b-ketoester (1), the
alkene (2) and the amine (7).
With this library of synthetic endoperoxides in hands, we
evaluated the antileishmanial properties of 3-methoxy-1,2-
dioxanes that previously showed the highest bioactivity as anti-
malarials, structurally characterized by the presence of an amino-
propyl side-chain at 4-position and by a 3,4-cis stereochemistry.We
started our investigation selecting Leishmania donovani as reference
strain indicative of the leishmaniasis in the Old World. The bioac-
tivity against the extracellular promastigote forms of L. donovani
Scheme 1. Reagents and conditions: a) 1 (2 equiv.), Mn(OAc)3 (5mol%), Mn(OAc)2 (5mol%), O2 (filled balloon), AcOH (3mL/mmol), rt, 4e12 h (70e90%); b) CSA (15mol%), MeOH
(2mL/mmol), reflux, 12e24 h (75e85%); c) DIBAL (2 equiv.), DCM (4mL/mmol), 20 C, 1 h (80e95%); d) DesseMartin periodinane (1.3 equiv.), DCM (5mL/mmol), rt, 1 h (80e90%);
e) i. Ar(CH2)3NH2 (7, 1 equiv.), MeOH (6mL/mmol), rt, 5e7 h; ii. NaBH4 (1.5 equiv.), 0 C to rt, 1.5 h (80e90%, 2 steps). For more details on the synthesis see Ref. [19].
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centration of compound required to inhibit the parasite growth by
50% (Table 1). When an interesting bioactivity was observed, the
corresponding cytotoxicity on Vero cells was also evaluated
(Table 1). The collected data proved to be very interesting. The two
different heteroaromatic systems (7-chloroquinolin-4-amine for 8a
and imidazole for 8b) on the C4-side chain confer the corre-
sponding endoperoxides a potent antileishmanial activity (IC50
range 1.6 mMe5.5 mM). In particular, the imidazole derivative 8b
displays a slightly lower potency, but also a significantly reduced
cytotoxicity leading to a good selectivity index (SI¼ 13.5). Preser-
ving the imidazole as the best substituent on C4, the nature of the
alkyl groups at C3 and C6 was investigated, going from methyl to
butyl. Compounds 8c and 8d with two methyl groups at C6 are
inactive, suggesting that longer and more lipophilic substituents
are needed in this position, regardless of the chain present at C3.
Indeed, the tributyl derivative 8e holds an IC50 value of 6.2 mM,
comparable to that of the dibutyl derivative 8b. However, the
presence of a butyl at C3, instead of a methyl, seems to significantly
increase the cytotoxicity (CC50¼ 32.5 mM).
The antileishmanial activity on L. donovani promastigotes was
also studied for the intermediates 3a, 4a and 5a, obtained in the
synthesis of the aminopropyl imidazole derivative 8b, which
showed the most promising bioactivity. The hemiketal 3a, the ketal
4a (both the isomers 3,4-cis and 3,4-trans), and the alcohol 5a (both
the isomers 3,4-cis and 3,4-trans) revealed to be all inactive at the
tested concentration (Table 1). These findings demonstrate the
crucial role played by the nature of the C4-side chain in deter-
mining the antileishmanial activity.
Finally, we tested the natural endoperoxide artemisinin and its
semi-synthetic derivative artesunate on L. donovani promastigotes
(Table 1). They displayed no antileishmanial activity under our
bioassay conditions (40 mM of peroxide, promastigote forms of
L. donovani MHOM/NP/02/BPK282/0cl4). These results are inagreement with some data reported in the literature for these
compounds (artemisinin: IC50¼100e160 mM [16a, 20]; artesunate:
no cell death at 100 mg/mL [21]). These data allow us to infer that
our synthetic, structurally simple compounds, i.e. 3-methoxy-1,2-
dioxanes, display an excellent antileishmanial potency on
L. donovani, compared to natural artemisinin and its semi-synthetic
derivative artesunate. Indeed, the IC50 values on L. donovani pro-
mastigotes recorded for our endoperoxides are comparable to those
of the most active antileishmanial artemisinin derivatives
BB200e201 and BB241e242 (Fig. 2). Moreover, to the best of our
knowledge, we present here the first study on the antileishmanial
activity of fully synthetic endoperoxides on L. donovani, whereas
the trioxolanes reported in Fig. 2 have been tested only on
L. infantum [18].
2.2. Synthesis of the second series of endoperoxides and in vitro
susceptibility tests against L. donovani promastigotes
Prompted by the first good bioactivity results obtained for 4-
aminopropyl-substituted 3-methoxy-1,2-dioxanes (8a, 8b, and 8e;
Table 1) and on the basis of the preliminary structure-activity re-
lationships (SARs) emerged, we designed some new endoperoxides
to be tested against L. donovani promastigotes. In particular, we
planned the following structural modifications: i) replacement of
the imidazole with a triazole (8f, Scheme 2), to investigate the
impact of the heteroaromatic system; ii) replacement of the butyl
chains on C6 with phenyl groups (8g-i, Scheme 2) or a group
derived from b-pinene (8j-k, Scheme 2), to vary the lipophilic
properties of the endoperoxides; iii) insertion of a fluconazole-type
moiety on C4-side chain (8m, Scheme 2), being fluconazole an
antifungal drug also active against some Leishmania spp. [22]; iv)
introduction of a phosphonium salt on the C4-side chain (8n-q,
Scheme 2), a group that is known to direct bioactive molecules to
mitochondria [23]. Finally, we decided also to evaluate the effect of
Table 1
Inhibitory activity of the first series of endoperoxides against promastigotes of L. donovani, cytotoxicity in mammalian kidney epithelial cells (Vero) and selectivity indexes.
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cis-4a
> 40 nd nd
trans-4a
> 40 nd nd
cis-5a
> 40 nd nd
trans-5a
> 40 nd nd
Artemisinin > 40 nd nd
Artesunate > 40 nd nd
Amphotericin B 0.3 200.0 666.7
a Compounds tested as racemates.
b IC50 represents the concentration of a compound that causes 50% growth inhibition. The experimental error was in the range 1e2.5 mM. See Supporting Information for
details.
c CC50 represents 50% cytotoxic concentration on Vero cells.
d Selectivity index (SI)¼ CC50/IC50. nd¼ not determined due to the low antileishmanial potency.
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Scheme 2. Reagents and conditions: a) 1 (2 equiv.), Mn(OAc)3 (5mol%), Mn(OAc)2 (5mol%), O2 (filled balloon), AcOH (3mL/mmol), rt, 4 h; b) CSA (15mol%), MeOH (2mL/mmol),
reflux, 24 h; c) LiAlH4 (1 equiv.), THF (5mL/mmol), 0 C, 1 h; d) i. DesseMartin periodinane (1.2 equiv.), DCM (5mL/mmol), 0 C to rt, 1 h; ii. amine (7, 1 equiv.), MeOH (6mL/mmol),
rt, overnight; iii. NaBH4 (1.5 equiv.), 0 C to rt, 1.5 h (overall yields reported); e) i. NaH (1.1 equiv.), propargyl bromide (1.2 equiv.), THF (5.5mL/mmol), 0 C to rt, overnight; ii. azide
(10, 1 equiv.), Cu(PPh3)3Br (10mol%), DCM (16mL/mmol), rt, overnight (overall yields reported). dr indicates 3,4-cis/3,4-trans ratio. pin¼ pinene-derived scaffold. nd¼ not
determined due to the complexity of the reaction mixture. Unless noted otherwise, the final products 8 show 3,4-cis stereochemistry.
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some 3,4-trans analogues (8k, 8l, and 8o, Scheme 2).
The new designed compounds were synthesized initially by
exploiting the already optimized strategy leading to the alcohol 5
(Scheme 2). This product served as common intermediate to
approach both new aminopropyl derivatives (8f-l, Scheme 2)
through an oxidation/reductive amination sequence, and the new
triazolyl ethers (8m-q, Scheme 2) through an alkylation/click
cycloaddition sequence.
The Mn-promoted cycloaddition applied to the selected sub-
strates 1 and 2 provided the desired new hemiketals 3e-h with
good yields (step a, Scheme 2), except for 3f which displayed poor
solubility and a difficult purification. The process showed in all the
examples a marked diastereoselectivity in favor of the 3,4-cis iso-
mers. The ketalization step generally proceeded with yields around
50% (step b, Scheme 2) and afforded two C3 epimers, also when
using a pure cis hemiketal as the starting material. The key inter-
mediate alcohols 5 were obtained in good yields through a che-
moselective ester reduction (step c, Scheme 2) not affecting theendoperoxide OeO bond. Usually, the ketalization and the reduc-
tion steps were carried out on mixtures of 3,4-cis/3,4-trans endo-
peroxides, then the two C3-epimers of 5 were easily separated by
flash chromatography. Starting from 5, the two series of products 8
were synthesized. Exploiting the oxidation/reductive amination
sequence (step d, Scheme 2), the aminopropyl derivatives (8f-l)
were isolated in good to high overall yields. The second family of
designed endoperoxides, characterized by an ether and a triazole as
linker (8m-q, Scheme 2), was obtained through an alkylation re-
action followed by a click cycloaddition (step e, Scheme 2), dis-
playing both moderate yields. However, no further optimizations
were carried out for these reactions, since the desired products
were obtained pure in sufficient amounts to be assayed and fully
characterized.
The new twelve endoperoxides (8f-q) were tested on promas-
tigotes of L. donovani and the corresponding cytotoxicity on Vero
cells was evaluated for compounds showing antileishmanial ac-
tivity (Table 2).
The replacement of imidazole with 1,2,4-triazole in the C4-side
Table 2
Inhibitory activity of the second series of endoperoxides against promastigotes of L. donovani, cytotoxicity in mammalian kidney epithelial cells (Vero) and selectivity indexes.
Compounda L. donovani promastigotes IC50 (mM)b Vero CC50 (mM)c SId
8f





















Table 2 (continued )




> 40 nd nd
Fluconazole > 40 nd nd
a Except for pinene-derivatives, the compounds were tested as racemates.
b IC50 represents the concentration of a compound that causes 50% growth inhibition. The experimental error was in the range 1e2.5 mM. See Supporting Information for
details.
c CC50 represents 50% cytotoxic concentration.
d Selectivity index (SI)¼ CC50/IC50.
e Mixture of 3,4-cis diastereoisomers.
f Mixture of 3,4-trans diastereoisomers. nd¼ not determined due to the low antileishmanial potency.
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Table 1 vs. 8f, Table 2) confirming the crucial pharmacophoric role
played by an imidazole ring in this position. The presence of phenyl
groups instead of butyl chains on C6 does not affect bioactivity [24]
(8b, Table 1 vs. 8g, Table 2) whereas the cytotoxicity resulted
slightly increased (CC50¼ 50 mM), with a halved selectivity index.
As already noticed for C6-butyl derivatives (8b and 8e, Table 1), also
for C6-phenyl derivatives the introduction of a butyl at C3 signifi-
cantly enhances the cytotoxicity (8h vs. 8g, Table 2). Minor conse-
quences on both activity and selectivity are observed by inserting a
para-F substituent on C6-phenyl rings (8i vs. 8g, Table 2). On the C6
position of the endoperoxide, we evaluated also the presence of the
bicyclic system derived from beta-pinene ((1S,5S)-2(10)-pinene)
(8j-k, Table 2). In this case, the synthetic strategy led to the for-
mation of a further stereocenter at C6 and the products were ob-
tained as complex mixtures of stereoisomers (eight
diastereoisomers formed). Wewere able to separate the four 3,4-cis
isomers (8j) from the four 3,4-trans ones (8k), but the products 8j
and 8k were assayed as mixture of isomers. Moreover, we tested
two fractions of the 3,4-trans derivative 8k (8k-A and 8k-B) char-
acterized by a different isomers composition. The antileishmanial
properties of all the pinene derivatives are good and their cyto-
toxicity is particularly low. The best result was recorded for 3,4-
trans 8k-B displaying IC50 value of 8 mM, CC50 value of 276.5 mM and
SI of 34.6. The higher activity of 8k-B compared to 8k-A demon-
strates that some 3,4-trans isomers are more potent than others.
Therefore, further investigations are currently underway in our
laboratory to separate the diastereomeric mixtures and to identify
the most potent scaffolds.
Replacement of butyl chains at C6 with both phenyl groups (8g-
i) or the pinene-derived scaffold (8j-k) provides endoperoxides
with good antileishmanial performances and it confirms that this
class of compounds requires significant lipophilic substituents in
this position.
With the aim to better understand the impact of the 3,4-relative
stereochemistry on the bioactivity, we tested 8l, the 3,4-trans
analogue of one of the most active products (8b). 8l displays an
activity (IC50¼ 4 mM) similar to the 3,4-cis analogue 8b, but with a
significantly improved selectivity (SI¼ 35), enough to become one
of the best antileishmanial hit of this family.
Another structural modification we examined was the intro-
duction on C4-side chain of a portion of the antifungal flucona-
zole. This moiety was bound to the endoperoxide through anether linkage and one of the two 1,2,4-triazoles of fluconazole
was replaced by a 1,2,3-triazole (8m, Scheme 2 and Table 2). The
antileishmanial properties of this sort of hybrid product 8m are
good, similar to those of the corresponding imidazole derivative
8b (Table 1), one of the lead compounds of the series. For com-
parison, we assayed also fluconazole on L. donovani promasti-
gotes (Table 2) and the antifungal drug itself revealed to be
inactive at the highest tested concentration (40 mM). This result
suggests that the antileishmanial activity of fluconazole-inspired
compound 8m is related to the presence of both the endoper-
oxide system and of a suitable heteroaromatic ring system on the
C4 side-chain.
The last group of new molecules reported in this article is
characterized by a phosphonium salt on the C4-side chain bound
through an ether/triazole linker (8n-q, Scheme 2 and Table 2).
The purpose of introducing this peculiar ionic pendant was to
investigate the possibility to direct our bioactive molecules to
mitochondria [23]. The lipophilic cation was inserted on the core
peroxide scaffolds bearing the most promising substituents on C3
(methyl) and on C6 (butyl, 8n-o, and phenyl, 8p). The phospho-
nium/butyl derivative 8n (Table 2) is slightly less active and se-
lective then the corresponding imidazole derivative 8b (Table 1),
although owns good antileishmanial properties. The corre-
sponding 3,4-trans analogue 8o is less effective than 3,4-cis 8n
(Table 2), in contrast to what displayed by diasteroisomers of the
imidazole/butyl compounds 8b and 8l (Tables 1 and 2, respec-
tively). The best behavior of the phosphonium-series was ob-
tained for the phosphonium/phenyl derivative 8p (Table 2). With
IC50¼11.5 mM, CC50¼ 280 mM, and SI¼ 24.3, it revealed to be one
of the most promising products of the family. For comparison, we
synthesized and tested also the C6-methyl substituted compound
8q (Scheme 2, Table 2). As previously observed for the corre-
sponding imidazole/methyl derivative 8c (Table 1), also the
phosphonium/methyl derivative 8q is inactive (Table 2), further
confirming that: i) the C4-side chain alone does not provide an
antileishmanial activity and that a suitable decorated endoper-
oxide moiety is required; ii) a lipophilic group longer than methyl
must be present at C6, regardless of the nature of the C4-side
chain.
Since we found that the phosphonium-substituted endoperox-
ides display a good antileishmanial bioactivity, further in-
vestigations are currently underway in order to verify whether
mitochondria might be a biological target of our compounds.
Table 3
Comparison of inhibitory activity of compounds 8b, 8l, 8j, 8k-B, 8m, 8p against promastigotes of L. donovani, L. major, L. tropica, L. infantum.
Compounda L. donovani promastigotes IC50 (mM)b L. major promastigotes IC50 (mM)b L. tropica promastigotes IC50 (mM)b L. infantum promastigotes IC50 (mM)b
3,4-cis 8b 5.5 11.8 8.9 3.0
3,4-trans 8l 4.0 3.2 3.0 2.5
3,4-cis 8j 16.3 15.5 35.0 6.0
3,4-trans 8k-B 8.0 25.0 24.0 5.0
3,4-cis 8m 16.0 38.4 38.0 12.0
3,4-cis 8p 11.5 2.6 6.0 10.0
a Except for pinene-derivatives, the compounds were tested as racemates.
b IC50 represents the concentration of a compound that causes 50% growth inhibition. The experimental error was in the range 1e2.5 mM. See Supporting Information for
details.
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infantumpromastigotes
The six most promising compounds in terms of activity and
selectivity were further investigated for their antileishmanial effi-
cacy on the promastigote forms of three other parasitic species, i.e.
L. tropica, L. major and L. infantum (Table 3). In particular, we
selected the most active products of the C4-imidazolyl series (3,4-
cis 8b and 3,4-trans 8l C6-butyl derivatives; 3,4-cis 8j and 3,4-trans
8k-B C6-pinene derivatives), of the C4-phosphonium series (3,4-cis
C6-phenyl derivative 8p) and the fluconazole-inspired compound
8m.
The products revealed to be active against all tested strains and
the IC50 values are particularly low for L. infantum, ranging from 2.5
to 12 mM. The antileishmanial activity of C6-phenyl C4-
phosphonium product 8p are noticeable against L. major (IC50
2.6 mM) and L. tropica (IC50 6 mM). However, the most interesting
bioactivity profile is shown by 3,4-trans C6-butyl C4-imidazole
endoperoxide 8l, which exhibits excellent performances against
all the studied Leishmania strains (IC50 range from 2.5 to 4 mM).
2.4. Evaluation of in vitro activity against L. donovani amastigotes
Considering the promising results obtained, the structural fea-
tures of 8b, 8l, 8j, 8k-B, 8p, 8m were identified as crucial for the
antileishmanial activity. Therefore, these compounds were selected
to be tested for their efficacy against the amastigote stage of
L. donovani that has pharmacological relevance because this form is
specifically found in human cells (Table 4). The amastigote assay
was performed by using metacyclic promastigotes to infect differ-
entiated THP-1 macrophagic cells; amastigotes transformed from
metacyclic promastigotes proliferated inside host macrophages.
In general, all the tested compounds exhibited a slightly higher
inhibitory effect on promastigotes than on amastigotes, but it is
noteworthy that the endoperoxides activity observed on promas-
tigotes was preserved on amastigotes (Table 4). In fact, the very
promising antileishmanial artemisinin derivatives BB200e201 and
BB241e242 (Fig. 2), despite the high in vitro activity against
L. donovani promastigotes, revealed to be inactive on intra-
macrophage amastigote stage [17c]. Thus, these findings confirmTable 4
Comparison of inhibitory activity of compounds 8b, 8l, 8j, 8k-B, 8m, 8p aga







a Except for pinene-derivatives, the compounds were tested as racemate
b IC50 represents the concentration of a compound that causes 50% grow
Supporting Information for details.that our synthetic endoperoxides are promising compounds for a
pharmaceutical development.
In details, the promastigotes/amastigotes results are particularly
similar for pinene-, fluconazole-, and phosphonium-derivatives
(8j-k, 8m and 8p, respectively), whereas for the two isomers of
butyl/imidazole scaffold (8b and 8l) we observed a halved activity
on amastigotes. However, we noticed that the best anti-amastigotes
properties are displayed by the two 3,4-trans compounds 8l and 8k-
B.
3. Conclusions
In order to identify novel antileishmanial agents, a library of 22
new and variously functionalized endoperoxides was synthetized
and their antileishmanial activity was evaluated. Six compounds
proved to be significantly active in in vitro assays against
L. donovani, L. tropica, L. major and L. infantum promastigotes and
against L. donovani amastigotes, with low cytotoxic effects towards
mammalian cells. These six hits show an excellent performance in
terms of potency and selectivity. Our findings suggest that the
selected compounds act on biological targets specific for Leish-
mania, or that their internalization process is more efficient for
parasitic cells rather than mammalian cells. Further investigations
are underway to identify the parasite target/s.
Concerning the mechanism of action of endoperoxides, even if
the exact mechanisms remains controversial, it is nowadays
accepted that the role of endoperoxides against the malaria para-
sites involves the cleavage of OeO bond by Fe(II), leading to the
generation of cytotoxic oxygen-centered radicals [25]. Plasmodial
and leishmanial parasites exhibit some common features, such as
the strong dependence on iron/heme supply by the mammalian
host cell [26]. Evidences indicate that endoperoxides react rapidly
with iron (II) resulting in the formation of oxygen- and carbon-
centered radicals and impairing mitochondrial functions in para-
sites of the Leishmania genus [27]. In view of these studies, we
speculate that the interactionwith iron, the oxidative stress and the
interference with the cellular respiration could represent one
mechanism by which our synthetic endoperoxides act on Leish-
mania. Studies are currently underway in our laboratories to
investigate the mechanism of action of these structurally simpleinst promastigotes and amastigotes of L. donovani.








th inhibition. The experimental error was in the range 1e2.5 mM. See
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In summary, in the reported study we demonstrated: i) the
crucial pharmacophoric role played by the nature of the side-chain
in the C4-position, being the aminopropyl imidazole and the tri-
azolyl propyl phosphonium salt the two best substituents; ii) the
significant lipophilic requirements at C6-position, with n-butyl,
aryl and pinene-derived scaffold as best performing groups; iii) the
need of a short (methyl) chain at C3-position to minimize the
cytotoxicity. Furthermore, the good antileishmanial properties
shown by the fluconazole-endoperoxide hybrid 8m suggest that
the observed bioactivity is related to the concurrent presence of the
endoperoxide-system, being the antifungal drug itself inactive in
our system.
The obtained results demonstrate that our synthetic and
structurally simple 3-methoxy-1,2-dioxanes own a remarkable
antileishmanial potency that is far superior to those of artemisinin
and artesunate and comparable to the most active antileishmanial
artemisinin derivatives BB200e201, BB241e242 (Fig. 2).
It is noteworthy that the endoperoxide activity observed on
L. donovani promastigotes was preserved on amastigotes (Table 4),
thus confirming that this family of compounds can be pharma-
ceutically promising.
In conclusion, the excellent selective activity and the simple
synthesis of endoperoxides 8b, 8l, 8j, 8k-B, 8p, 8m highlight their




All of the commercial chemicals were purchased from Sigma
Aldrich, VWR, Alfa Aesar or TCI Chemicals, and used without
additional purifications. The 1H and 13C NMR spectrawere recorded
on a 400 NMR instrument with a 5mm probe. All chemical shifts
have been quoted relative to deuterated solvent signals; chemical
shifts (d) are reported in ppm and coupling constants (J) are re-
ported in Hertz. HPLC-LRMS analyses were performed on an Agi-
lent Technologies HP1100 instrument coupled with an Agilent
Technologies MSD1100 single-quadrupole mass spectrometer. A
Phenomenex Gemini C18 3 mm (100 3mm) column was
employed for the chromatographic separation and two different
analytical methods were used: method A: mobile phase H2O/
CH3CN, gradient from 30% to 80% of CH3CN in 8min, 80% of CH3CN
until 22min, then up to 90% of CH3CN in 2min, stop time at 25min;
flow rate 0.4mLmin1; method B: gradient analogous to method A
employing a mobile phase (H2O/CH3CN) containing 0.2% of formic
acid. Mass spectrometric detection was performed in full-scan
mode from m/z 50 to 2500, scan time 0.1 s in positive ion mode,
ESI spray voltage 4500 V, nitrogen gas 35 psi, drying gas flow rate
11.5mLmin1, fragmentor voltage 30 V. Almost all the synthesized
compounds were analyzed employing method A, compounds
analyzed with method B are specified. High-resolution MS (HRMS)
ESI analyses were performed on a LTQ Orbitrap XL (Thermo Sci-
entific) mass spectrometer. Melting point (mp) measurements
were performed on a Bibby Stuart Scientific SMP3 apparatus. Flash
chromatography purifications were carried out using VWR silica gel
(40e63 mm particle size). Thin-layer chromatography was per-
formed on Merck 60 F254 plates.
4.1.2. General procedure for the synthesis of 3-hydroxy-1,2-
dioxanes 3
The appropriate alkene 2 (8.5mmol) was added at room tem-
perature to a mixture of the desired b-keto ester 1 (2 equiv.),
Mn(OAc)3$2(H2O) (5mol%), and Mn(OAc)2$4(H2O) (5mol%) inacetic acid (2mL/mmol). The resulting homogeneous solution was
stirred at room temperature for 4 h under oxygen at atmospheric
pressure (O2 filled balloon) and the conversion was monitored by
TLC. The reactionmixturewas neutralizedwith NaOH (6M aqueous
solution, 50mL) and then made slightly basic by adding saturated
NaHCO3 solution. The aqueous phase was extracted with EtOAc
(3 25mL), the combined organic phases were dried (Na2SO4) and
the solvent evaporated to dryness under reduced pressure. 3-
Hydroxy-1,2-dioxanes 3 were purified by flash chromatography
on silica gel or by recrystallization.
4.1.2.1. Methyl 6,6-dibutyl-3-hydroxy-3-methyl-1,2-dioxane-4-
carboxylate (3a). Mobile phase for the chromatographic purifica-
tion: cyclohexane/ethyl acetate¼ 9/1 to 7/3.70% yield. 1H NMR
(400MHz, CDCl3) d 3.74 (s, 3H), 2.92 (dd, J¼ 13.1, 5.0 Hz, 1H), 2.09
(dd, J¼ 14.0, 13.1 Hz, 1H), 1.91e1.79 (m, 1H), 1.75 (dd, J¼ 14.0,
5.0 Hz, 1H), 1.62e1.13 (m, 11H), 1.49 (s, 3H), 0.96e0.87 (m, 6H). 13C
NMR (100MHz, CDCl3) d 172.1, 97.8, 81.2, 52.0, 44.5, 36.0, 30.8, 30.4,
25.3, 24.7, 24.2, 23.0, 23.0, 13.9, 13.8. HPLC (method B)-LRMS (ESI)
m/z 271.2 [MH2OþH]þ, 306.2 [Mþ H2O]þ, 372.2 [Mþ K]þ, 599.2
[2M þ Na]þ, Rt¼ 9.5min. HRMS (ESI)m/z [MH2O þ H]þ calcd for
C15H27O4: 271.1904, found: 271.1890.
4.1.2.2. Methyl 3-hydroxy-3-methyl-6,6-diphenyl-1,2-dioxane-4-
carboxylate (3e). The crude mixture was dissolved in the mini-
mum amount of CH2Cl2/MeOH mixture and the pure product was
crystallized by adding cold cyclohexane. 78% yield.
Mp¼ 168e170 C. 1H NMR (400MHz, CDCl3) d 7.54 (d, J¼ 8.0 Hz,
1H), 7.40 (t, J¼ 8.0 Hz, 1H), 7.34e7.21 (m, 8H), 3.75 (s, 3H),
2.93e2.81 (m, 3H), 1.41 (s, 3H). 13C NMR (100MHz, CDCl3) d 171.9,
143.1, 140.7, 128.5, 128.4, 128.0, 127.4, 126.7, 125.7, 98.5, 85.2, 52.2,
45.4, 31.8, 24.5. HPLC-LRMS (ESI) m/z 311.0 [MH2O þ H]þ, 346.0
[M þ H2O]þ, 679.0 [2M þ Na]þ, Rt¼ 10.3min. HRMS (ESI) m/z
[M þ H2O]þ, calcd for C19H22O6: 346.1416, found: 346.1424.
4.1.3. General procedure for the synthesis of 3-methoxy-1,2-
dioxanes 4
(1S)-(þ)-Camphorsulfonic acid (15 mol%) was added at room
temperature to a solution of the desired 3-hydroxy-1,2-dioxane 3
(5.72mmol) in anhydrousmethanol (2mL/mmol). Themixturewas
stirred at 65 C for 24 h. The conversion was monitored by TLC.
Then, the solvent was removed under reduced pressure and DCM
(15mL) was added. The organic phase was washed at 0 C with
NaHCO3 (saturated aqueous solution, 15mL), dried (Na2SO4) and
evaporated to dryness. 3-Methoxy-1,2-dioxanes 4 were isolated
after flash chromatography on silica gel.
The assayed product 4a (cis and trans isomers) was synthesized
following a previously reported procedure [19a] and the spectro-
scopic data and physical properties of the obtained products were
identical to the previously reported ones.
4.1.3.1. Methyl 3-methoxy-3-methyl-6,6-diphenyl-1,2-dioxane-4-
carboxylate (4e). Mobile phase for the chromatographic purifica-
tion: cyclohexane/ethyl acetate¼ 9/1.47% yield. 1H NMR (400MHz,
CDCl3) d 7.54 (d, J¼ 8.0 Hz, 2H), 7.40 (t, J¼ 8.0 Hz, 2H), 7.34e7.19 (m,
6H), 3.72 (s, 3H), 3.45 (s, 3H), 3.04e2.97 (m,1H), 2.78e2.70 (m, 2H),
1.36 (s, 3H). 13C NMR (100MHz, CDCl3) d 171.1, 143.5, 141.0, 128.4,
128.2, 128.0, 127.3, 127.0, 126.3, 101.2, 85.4, 52.0, 49.2, 46.2, 31.2,
19.4. HPLC-LRMS (ESI)m/z 311.0 [M-OMe]þ, 365.0 [Mþ Na]þ, 685.6
[2M þ H]þ, Rt¼ 11.2min. HRMS (ESI) m/z [M þ Na]þ, calcd for
C20H22NaO5: 365.1359, found: 365.1368.
4.1.4. General procedure for the synthesis of 4-hydroxymethyl-1,2-
dioxanes 5
LiAlH4 (1 equiv) was added at 0 C to a solution of 3-methoxy-
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mixture was stirred at 0 C for 1 h (conversion monitored by TLC).
The reactionwas quenched at 0 Cwith NaHCO3 (saturated aqueous
solution, 15mL), the THF was dried under reduced pressure and the
mixture was extracted with EtOAc (3 15mL). The organic phases
were collected, dried (Na2SO4) and evaporated to dryness. 4-
Hydroxymethyl-1,2-dioxanes 5 were isolated after flash chroma-
tography on silica gel. The chromatographic purification allowed to
separate cis and trans isomers of the products 5.
4.1.4.1. (6,6-Dibutyl-3-methoxy-3-methyl-1,2-dioxan-4-yl)methanol
(5a). Mobile phase for the chromatographic purification: cyclo-
hexane/diethyl ether¼ 1/1.96% yield.
Cis-5a: 1H NMR (400MHz, CDCl3) d 3.89 (dd, J¼ 11.5, 3.1 Hz,1H),
3.53 (dd, J¼ 11.6, 3.7 Hz, 1H), 3.34 (s, 3H), 2.05 (t, J¼ 12.0 Hz, 1H),
1.97e1.86 (m, 2H), 1.55e1.16 (m, 12H), 1.35 (s, 3H), 0.94e0.88 (m,
6H). 13C NMR (100MHz, CDCl3) d 103.2, 81.8, 62.9, 48.5, 39.8, 36.3,
31.4, 29.8, 25.4, 24.8, 23.2, 23.2, 18.8, 14.0, 13.9. HPLC (method B)-
LRMS (ESI) m/z 243.0 [M-OMe]þ, 257.2 [MH2O þ H]þ, 297.2
[M þ Na]þ, 313.0 [M þ K]þ, 571.0 [2M þ Na]þ, Rt¼ 9.1min. HRMS
(ESI) m/z [M þ Na]þ, calcd for C15H30NaO4: 297.2036, found:
297.2048.
Trans-5a: 1H NMR (400MHz, CDCl3) d 3.64 (dd, J¼ 10.6, 8.8 Hz,
1H), 3.54 (dd, J¼ 10.7, 5.9 Hz, 1H), 3.37 (s, 3H), 2.33e2.17 (m, 1H),
1.76e1.64 (m, 1H), 1.64 (dd, J¼ 13.3, 3.5 Hz, 1H), 1.28 (s, 3H),
1.57e1.10 (m,12H), 0.91 (t, J¼ 7.2 Hz, 3H), 0.90 (t, J¼ 7.2 Hz, 3H). 13C
NMR (100MHz, CDCl3) d 106.8, 84.2, 62.7, 49.1, 41.6, 36.6, 32.7, 32.6,
25.5, 25.4, 23.2, 23.1,14.1, 13.9,13.9. HPLC (method B)-LRMS (ESI)m/
z 257.2 [MH2O þ H]þ, 297.2 [M þ Na]þ, 313.2 [M þ K]þ, 571.2
[2M þ Na]þ, Rt¼ 8.5min. HRMS (ESI) m/z [M þ Na]þ, calcd for
C15H30NaO4: 297.2036, found: 297.2056.
4.1.4.2. (3-Methoxy-3-methyl-6,6-diphenyl-1,2-dioxan-4-yl)meth-
anol (5e). Mobile phase for the chromatographic purification:
cyclohexane/EtOAc¼ 8/2.88% yield.
Cis-5e: 1H NMR (400MHz, CDCl3) d 7.54 (d, J¼ 7.2 Hz, 2H), 7.37
(d, J¼ 7.2 Hz, 2H), 7.29e7.16 (m, 6H), 3.87 (dd, J¼ 3.6, 11.6 Hz, 1H),
3.61 (dd, J¼ 4.0, 11.6 Hz, 1H), 3.45 (s, 3H), 2.81 (dd, J¼ 13.2, 14.0 Hz,
1H), 2.52 (dd, J¼ 4.0, 14.0 Hz, 1H), 1.85 (dq, J¼ 3.6, 12.8 Hz, 1H), 1.23
(s, 3H). 13C NMR (100MHz, CDCl3) d 144.2, 141.8, 128.3, 128.2, 127.8,
127.1, 127.0, 126.1, 103.8, 86.1, 62.9, 48.9, 41.0, 31.4, 18.7. HPLC-LRMS
(ESI) m/z 297.0 [MH2O þ H]þ, 337.0 [M þ Na]þ, 353.0 [M þ K]þ,
Rt¼ 6.6min. HRMS (ESI) m/z [M þ Na]þ, calcd for C19H22NaO4:
337.1410, found: 337.1402.
4.1.5. General procedure for the synthesis of intermediate 4-
carbaldehyde-1,2-dioxanes 6
Alcohol 5 (0.3mmol) was dissolved in anhydrous CH2Cl2
(2.5mL/mmol) and DesseMartin periodinane (1.05 equiv.) was
added at 0 C. The solution was stirred at room temperature for 1 h
(conversion monitored by TLC). The solvent was removed under
reduced pressure and the crude was directly purified by flash
chromatography on silica gel (mobile phase: cyclohexane/
EtOAc¼ 9/1). The intermediate aldehyde 6 was immediately used
in the subsequent step. For further details on this transformation,
see Supporting Information.
4.1.6. General procedure for the synthesis of 4-aminopropyl
derivatives 8f-l (reductive amination)
Aldehyde 6 (0.2mmol) was dissolved in anhydrous MeOH
(2mL) and the desired amine 7 (1 equiv.) was added. The reaction
was stirred at room temperature overnight. The solution was then
cooled to 0 C and NaBH4 (1.5 equiv.) was added. The reaction
mixture was further stirred at room temperature for 1.5 h and
quenchedwith H2O (5mL). The organic solvent was removed underreduced pressure and the aqueous phase was extracted with AcOEt
(3 5mL). The combined organic phases were dried over Na2SO4
and evaporated under reduced pressure. The desired 4-
aminopropyl derivatives 8f-l were obtained pure after purifica-
tion by flash-chromatography on silica gel. For details on the syn-
thesis of amines 7, see Supporting Information.
The assayed products 8a-e were synthesized following a pre-
viously reported procedure [19d] and the spectroscopic data and
physical properties of the obtained products were identical to the
previously reported ones.
4.1.6.1. N-((6,6-dibutyl-3-methoxy-3-methyl-1,2-dioxan-4-yl)
methyl)-3-(1H-1,2,4-triazol-1-yl)propan-1-amine (8f). Mobile phase
for the chromatographic purification: CH2Cl2/MeOH¼ 9/1.1H NMR
(400MHz, CDCl3) d 8.03 (s, 1H), 7.89 (s, 1H), 4.24 (t, J¼ 6.8 Hz, 2H),
3.24 (s, 3H), 2.68 (dd, J¼ 4.0, 12.0 Hz, 1H), 2.53 (t, J¼ 6.8 Hz, 2H),
2.46 (dd, J¼ 8.0, 11.6 Hz, 1H), 2.00 (quintet, J¼ 6.8 Hz, 2H),
1.95e1.81 (m, 2H), 1.60 (t, J¼ 12.8 Hz, 1H), 1.52e1.35 (m, 3H),
1.35e1.15 (m, 9H), 1.25 (s, 3H), 0.90e0.84 (m, 6H). 13C NMR
(100MHz, CDCl3) d 151.8, 143.0, 102.1, 81.8, 50.6, 48.5, 47.2, 46.4,
39.2, 36.3, 32.1, 31.4, 29.7, 25.4, 24.8, 23.2, 18.9, 14.0, 13.9. HPLC-
LRMS (ESI) m/z 383.2 [M þ H]þ, Rt¼ 9.6min. HRMS (ESI) m/z
[M þ H]þ, calcd for C20H39N4O3: 383.3017, found: 383.3025.
4.1.6.2. 3-(1H-imidazol-1-yl)eN-((3-methoxy-3-methyl-6,6-
diphenyl-1,2-dioxan-4-yl)methyl)propan-1-amine (8g). Mobile
phase for the chromatographic purification: CH2Cl2/MeOH¼ 9/1.1H
NMR (400MHz, CDCl3) d 7.57 (d, J¼ 6.8 Hz, 2H), 7.49 (s, 1H), 7.42 (d,
J¼ 7.2 Hz, 2H), 7.33e7.20 (m, 6H), 7.07 (s, 1H), 6.93 (s, 1H), 4.06 (t,
J¼ 6.8 Hz, 2H), 3.45 (s, 3H), 2.77 (dd, J¼ 4.0, 12.0 Hz, 1H), 2.73 (dd,
J¼ 13.6, 4.0 Hz, 1H), 2.64e2.57 (m, 1H), 2.59 (t, J¼ 6.8 Hz, 2H), 2.49
(t, J¼ 12.4 Hz, 1H), 1.95 (quintet, J¼ 6.8 Hz, 2H), 1.90e1.83 (m, 1H),
1.21 (s, 3H). 13C NMR (100MHz, CDCl3) d 144.4, 141.8, 137.1, 129.3,
128.2, 128.1, 127.6, 127.0, 126.0, 118.8, 102.8, 86.1, 50.3, 48.8, 46.5,
44.6, 40.4, 33.5, 31.1, 18.6. HPLC-LRMS (ESI) m/z 422.2 [M þ H]þ,
444.2 [M þ Na]þ, Rt¼ 6.8min. HRMS (ESI) m/z [M þ H]þ, calcd for
C25H32N3O3: 422.2438, found: 422.2446.
4.1.6.3. N-((3-butyl-3-methoxy-6,6-diphenyl-1,2-dioxan-4-yl)
methyl)-3-(1H-imidazol-1-yl)propan-1-amine (8h). Mobile phase
for the chromatographic purification: CH2Cl2/MeOH¼ 9/1.1H NMR
(400MHz, CDCl3) d 7.54 (d, J¼ 7.3 Hz, 2H), 7.50 (s, 1H), 7.37 (t,
J¼ 7.5 Hz, 2H), 7.30e7.20 (m, 6H), 7.05 (s, 1H), 6.92 (s, 1H), 4.05 (t,
J¼ 6.8 Hz, 2H), 3.41 (s, 3H), 2.80e2.72 (m, 2H), 2.66e2.51 (m, 3H),
2.12e1.96 (m, 3H), 1.67 (ddd, J¼ 15.6, 10.7, 5.4 Hz, 1H), 1.55 (ddd,
J¼ 5.6, 11.2, 16.8 Hz, 1H), 1.15e1.03 (m, 2H), 0.98e0.82 (m, 3H), 0.73
(t, J¼ 7.3 Hz, 3H). 13C NMR (100MHz, CDCl3) d 144.1, 141.8, 137.1,
130.0, 129.2, 128.2, 128.1, 127.6, 127.0, 126.9, 126.1, 118.8, 104.1, 86.0,
49.8, 48.3, 46.5, 44.6, 35.5, 33.2, 31.5, 31.1, 25.6, 22.6, 13.6. HPLC-
LRMS (ESI) m/z 464.2 [M þ H]þ, Rt¼ 8.8min. HRMS (ESI) m/z
[M þ H]þ, calcd for C28H38N3O3: 464.2908, found: 464.2900.
4.1.6.4. N-((6,6-bis(4-fluorophenyl)-3-methoxy-3-methyl-1,2-
dioxan-4-yl)methyl)-3-(1H-imidazol-1-yl)propan-1-amine (8i).
Mobile phase for the chromatographic purification: CH2Cl2/
MeOH¼ 9/1.1H NMR (400MHz, CDCl3) d 7.48 (dd, J¼ 8.6, 5.4 Hz,
3H), 7.16 (dd, J¼ 8.8, 5.4 Hz, 2H), 7.08 (t, J¼ 8.7 Hz, 3H), 6.93 (t,
J¼ 8.7 Hz, 3H), 4.04 (t, J¼ 6.7 Hz, 2H), 3.40 (s, 3H), 2.75 (dd, J¼ 12.0,
3.9 Hz,1H), 2.67e2.52 (m, 4H), 2.43 (t, J¼ 13.6 Hz,1H),1.95 (quintet,
J¼ 6.9 Hz, 2H), 1.79 (ddd, J¼ 16.0, 8.0, 3.9 Hz, 1H), 1.19 (s, 3H). 13C
NMR (100MHz; CDCl3) d 162.1 (d, J¼ 246.0 Hz), 161.9 (d,
J¼ 244.0 Hz), 139.9 (d, J¼ 4.0 Hz), 137.3 (d, J¼ 3.0 Hz), 137.1 (bs),
129.5 (bs), 128.8 (d, J¼ 8.0 Hz), 128.1 (d, J¼ 8.0 Hz), 118.8 (bs), 115.3
(d, J¼ 21.3 Hz), 115.0 (d, J¼ 21.4 Hz), 102.7, 85.4, 50.1, 48.9, 46.5,
40.1, 33.8, 30.6, 29.7, 18.6. HPLC-LRMS (ESI) m/z 458.2 [M þ H]þ,
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C25H30F2N3O3: 458.2250, found: 458.2240.
4.1.6.5. 3-(1H-imidazol-1-yl)eN-(((1R,5S)-60-methoxy-6,6,60-trime-
thylspiro[bicyclo[3.1.1]heptane-2,3'-[1,2]dioxan]-50-yl)methyl)
propan-1-amine (8j). Mobile phase for the chromatographic puri-
fication: CH2Cl2/MeOH/NH4OH¼ 9/1/0.01. By means of the chro-
matographic purification we were able to separate the 3,4-cis
products 8j from the 3,4-trans ones 8k, whereas the mixtures of
compounds sharing the same 3,4 relative configuration remained
inseparable. The product 8j was assayed as mixture of 4 di-
astereoisomers (as shown by OMe signals in the 1H NMR spec-
trum), characterized by the 3,4-cis configuration. However, it was
not possible to precisely determine the diastereomeric ratio,
because both the 1H NMR and UV/MS-HPLC signals were largely
overlying. The identity of the product was confirmed by MS anal-
ysis. HPLC-LRMS (ESI) m/z 378.2 [M þ H]þ, 400.2 [M þ Na]þ, 416.2
[M þ K]þ, Rt¼ 5.5e7.0min. HRMS (ESI) m/z [M þ H]þ, calcd for
C21H36N3O3: 378.2751, found: 378.2762.
4.1.6.6. 3-(1H-imidazol-1-yl)eN-(((1R,5S)-60-methoxy-6,6,60-trime-
thylspiro[bicyclo[3.1.1]heptane-2,3'-[1,2]dioxan]-50-yl)methyl)
propan-1-amine (8k). Mobile phase for the chromatographic pu-
rification: CH2Cl2/MeOH/NH4OH¼ 9/1/0.01. By means of the chro-
matographic purification we were able to separate the 3,4-cis
products 8j from the 3,4-trans ones 8k, whereas the mixtures of
compounds sharing the same 3,4 relative configuration remained
inseparable. The product 8k-A was assayed as mixture of 4 di-
astereoisomers (as shown by OMe signals in the 1H NMR spec-
trum), characterized by the 3,4-trans configuration. However, it was
not possible to precisely determine the diastereomeric ratio,
because both the 1H NMR and UV/MS-HPLC signals were largely
overlying. The product 8k-B was assayed as mixture of 3 di-
astereoisomers (as shown by OMe signals in the 1H NMR spec-
trum), characterized by the 3,4-trans configuration. However, it was
not possible to precisely determine the diastereomeric ratio,
because both the 1H NMR and UV/MS-HPLC signals were largely
overlying. The identity of the product was confirmed by MS anal-
ysis. HPLC (method B)-LRMS (ESI) m/z 378.2 [M þ H]þ, 400.2 [M þ
Na]þ, Rt¼ 1.1min. HRMS (ESI) m/z [M þ H]þ, calcd for C21H36N3O3:
378.2751, found: 378.2765.
4.1.6.7. N-((6,6-dibutyl-3-methoxy-3-methyl-1,2-dioxan-4-yl)
methyl)-3-(1H-imidazol-1-yl)propan-1-amine (8l). Mobile phase for
the chromatographic purification: CH2Cl2/MeOH¼ 9/1.1H NMR
(400MHz, CDCl3) d 7.54 (s, 1H), 7.06 (s, 1H), 6.94 (s, 1H), 4.07 (t,
J¼ 6.8 Hz, 2H), 3.35 (s, 3H), 2.74 (dd, J¼ 11.8, 7.2 Hz, 1H), 2.65 (t,
J¼ 6.7 Hz, 2H), 2.47 (dd, J¼ 11.7, 7.3 Hz, 1H), 2.20e1.9 (m, 3H), 1.75
(dd, J¼ 13.4, 3.4 Hz, 1H), 1.71e1.63 (m, 1H), 1.54e1.39 (m, 3H),
1.36e1.12 (m, 12H), 0.93e0.87 (m, 6H). 13C NMR (100MHz, CDCl3)
d 137.2, 129.3, 117.8, 107.0, 84.3, 50.3, 49.2, 46.3, 44.6, 44.6, 39.5,
36.7, 32.7, 31.2, 25.6, 25.4, 23.2, 23.2, 14.3, 14.0, 13.9. HPLC (method
B)-LRMS (ESI) m/z 350.2 [M-OMe]þ, 382.2 [M þ H]þ, Rt¼ 3.5min.
HRMS (ESI) m/z [M þ H]þ, calcd for C21H40N3O3: 382.3064, found:
382.3053.
4.1.7. General procedure for the synthesis of 4-propargyl ethers 9
Alcohol 5 (0.26mmol) was dissolved in anhydrous THF (1mL)
and the temperature was decreased to 0 C. NaH (1.1 equiv.) was
added and the mixture was stirred at 0 C for 1 h. Then, propargyl
bromide (1.2 equiv.) was added and the solutionwas stirred at room
temperature overnight (conversion monitored by TLC). The reac-
tion was quenched with NH4Cl (saturated aqueous solution, 3mL)
and the mixture was extracted with EtOAc (3 4mL). The com-
bined organic phases were dried over Na2SO4 and evaporatedunder reduced pressure. The desired 4-propargyl ethers 9 were
obtained pure after purification by flash-chromatography on silica
gel (mobile phase: cyclohexane/EtOAc¼ 9/1 to 7/3). The interme-
diate ethers 9 were immediately used in the subsequent step. The
not converted alcohols 5 were recovered during the chromato-
graphic purification. For further details on this transformation, see
Supporting Information.
4.1.8. General procedure for the synthesis of 4-triazolyl ether
derivatives 8m-q (click cycloaddition)
Propargyl ether 9 (0.14mmol) was dissolved in anhydrous
CH2Cl2 (1mL). The selected azide 10 (1 equiv.) and Cu(PPh3)3Br
(10mol%) were added. The mixture was stirred at room tempera-
ture overnight (conversion monitored by TLC). The crude reaction
was directly purified by flash-chromatography on silica gel (mobile
phase: CH2Cl2/MeOH¼ 9/1) furnishing the pure products 8m-q.
The not converted ether 9 and azide 10 were recovered during the
chromatographic purification. For details on the synthesis of azides
10, see Supporting Information.
4.1.8.1. 1-(4-(((6,6-dibutyl-3-methoxy-3-methyl-1,2-dioxan-4-yl)
methoxy)methyl)-1H-1,2,3-triazol-1-yl)-2-(2,4-difluorophenyl)-3-
(1H-1,2,4-triazol-1-yl)propan-2-ol (8m). Mobile phase for the
chromatographic purification: CH2Cl2/MeOH/NH4OH¼ 9/1/0.01.1H
NMR (400MHz, CDCl3) d 7.98 (s, 1H), 7.84 (s, 1H), 7.62 (s, 1H), 7.43
(ddd, J¼ 9.8, 8.3, 6.0 Hz, 1H), 6.79 (m, 2H), 5.38 (s, 1H), 4.89 (d,
J¼ 14.2 Hz, 1H), 4.82 (dd, J¼ 14.1, 1.8 Hz, 1H), 4.70 (dd, J¼ 14.3,
1.4 Hz, 1H), 4.59 (d, J¼ 12.0 Hz, 1H), 4.55 (d, J¼ 16.0 Hz, 1H), 4.27 (d,
J¼ 14.2 Hz, 1H), 3.63 (ddd, J¼ 9.3, 5.8, 2.3 Hz, 1H), 3.27 (s, 3H), 3.21
(dd, J¼ 9.3, 7.2 Hz, 1H), 2.19e2.11 (m, 1H), 1.92e1.85 (m, 1H),
1.60e1.16 (m, 15H), 0.94e0.88 (m, 6H). 13C NMR (100MHz, CDCl3)
d 163.1 (dd, J¼ 251.6, 12.4 Hz), 158.5 (dd, J¼ 244.0, 11.7 Hz), 152.1,
145.1, 145.1, 130.1 (dd, J¼ 9.5, 5.3 Hz), 124.5, 124.5, 112.1 (dd,
J¼ 20.9, 3.1 Hz), 104.3 (t, J¼ 26.5 Hz), 101.4, 81.5, 75.2 (d, J¼ 4.9 Hz),
71.8, 64.4, 55.8, 54.6, 48.5, 39.2, 36.3, 31.5, 31.5, 25.4, 24.9, 23.2,19.3,
14.1, 13.9, 1.0. HPLC (method B)-LRMS (ESI) m/z 615.2 [M þ Na]þ,




nium bromide (8n). Mobile phase for the chromatographic purifi-
cation: CH2Cl2/MeOH¼ 98/2 and then 95/5.1H NMR (400MHz,
CDCl3) d 8.27 (bs, 1H), 7.84e7.65 (m, 15H), 4.99 (bs, 2H), 4.56 (bs,
2H), 3.88 (m, 2H), 3.69 (m,1H), 3.30e3.23 (m,1H), 3.25 (s, 3H), 2.38
(bs, 2H), 2.16 (m, 1H), 1.92e1.83 (m, 1H), 1.75e1.15 (m, 13H), 1.28 (s,
3H), 0.93e0.85 (m, 6H). 13C NMR (100MHz, CDCl3) d 144.5 (bs),
135.2 (d, J¼ 3.0 Hz), 133.6 (d, J¼ 10.2 Hz), 130.6 (d, J¼ 12.6 Hz),
125.5 (bs), 117.7 (d, J¼ 86.5 Hz), 101.5, 81.6, 72.1, 64.4 (bs), 49.1 (d,
J¼ 19.6 Hz), 48.5, 39.2, 36.3, 31.6, 31.5, 25.4, 24.8, 23.3 (d,
J¼ 2.0 Hz), 23.2, 23.2, 19.8 (d, J¼ 53.3 Hz), 19.2, 14.1, 13.9. HPLC-
LRMS (ESI) m/z 658.2 [M Br]þ, Rt¼ 6.9min. HRMS (ESI) m/z
[M Br]þ, calcd for C39H53N3O4P: 658.3768, found: 658.3780.
4.1.8.3. (3-(4-(((6,6-dibutyl-3-methoxy-3-methyl-1,2-dioxan-4-yl)
methoxy)methyl)-1H-1,2,3-triazol-1-yl)propyl)triphenylphospho-
nium bromide (8o). Mobile phase for the chromatographic purifi-
cation: CH2Cl2/MeOH¼ 98/2 and then 95/5.1H NMR (400MHz,
CDCl3) d 8.26 (bs, 1H), 7.85e7.65 (m, 15H), 5.02 (bs, 2H), 4.59 (bs,
2H), 4.00e3.86 (m, 2H), 3.62e3.55 (m, 1H), 3.40e3.34 (m, 1H), 3.29
(s, 3H), 2.44e2.33 (m, 2H), 2.30e2.21 (m, 1H), 1.80 (dd, J¼ 13.6,
3.5 Hz, 1H), 1.73e1.64 (m, 1H), 1.54e1.09 (m, 12H), 1.25 (s, 3H),
0.92e0.84 (m, 6H). 13C NMR (100MHz, CDCl3) d 144.4 (bs), 135.2 (d,
J¼ 3.0 Hz), 133.6 (d, J¼ 10.0 Hz), 130.6 (d, J¼ 12.6 Hz), 125.5 (bs),
117.7 (d, J¼ 86.5 Hz), 106.2, 84.2, 70.3, 64.2, 49.2, 49.0 (d,
M. Ortalli et al. / European Journal of Medicinal Chemistry 170 (2019) 126e140138J¼ 19.6 Hz), 39.6, 36.7, 33.3, 32.7, 25.5, 25.4, 23.3 (d, J¼ 2.0 Hz),
23.2, 23.2, 19.9 (d, J¼ 53.1 Hz), 14.7, 14.0, 13.9. HPLC-LRMS (ESI) m/z
658.2 [M Br]þ, Rt¼ 6.5min. HRMS (ESI) m/z [M Br]þ, calcd for
C39H53N3O4P: 658.3768, found: 658.3777.
4.1.8.4. (3-(4-(((3-methoxy-3-methyl-6,6-diphenyl-1,2-dioxan-4-yl)
methoxy)methyl)-1H-1,2,3-triazol-1-yl)propyl)triphenylphospho-
nium bromide (8p). Mobile phase for the chromatographic purifi-
cation: CH2Cl2/MeOH¼ 9/1.1H NMR (400MHz, CDCl3) d 8.30 (bs,
1H), 7.86 (dd, J¼ 12.6, 7.9 Hz, 1H), 7.81e7.72 (m, 9H), 7.71e7.63 (m,
6H), 7.53 (d, J¼ 8.0 Hz, 2H), 7.35 (t, J¼ 7.7 Hz, 2H), 7.26e7.14 (m,
5H), 4.99 (bt, J¼ 6.2 Hz, 2H), 4.58 (d, J¼ 12.0 Hz, 1H), 4.54 (d,
J¼ 12.0 Hz, 1H), 3.96e3.86 (m, 2H), 3.69 (dd, J¼ 9.36, 5.40 Hz, 1H),
3.40e3.34 (m, 1H), 3.37 (s, 3H), 2.71 (dd, J¼ 13.6, 3.9 Hz, 1H),
2.39e2.25 (m, 3H), 2.13e2.03 (m, 1H), 1.15 (s, 3H). 13C NMR
(100MHz, CDCl3) d 144.5, 144.3, 141.8, 135.2 (d, J¼ 3.0 Hz), 133.6 (d,
J¼ 10.2 Hz), 130.6 (d, J¼ 12.6 Hz), 128.3, 128.1, 127.5, 127.1, 126.9,
126.0, 125.6, 117.8 (d, J¼ 86.5 Hz), 102.1, 85.7, 71.4, 64.3, 49.0 (d,
J¼ 19.3 Hz), 48.7, 40.4, 32.8, 23.4 (d, J¼ 3.0 Hz), 19.7 (d, J¼ 53.2 Hz),
18.9. HPLC-LRMS (ESI) m/z 698.2 [M Br]þ, Rt¼ 8.5min. HRMS




nium bromide (8q). Mobile phase for the chromatographic purifi-
cation: CH2Cl2/MeOH¼ 9/1.1H NMR (400MHz, CDCl3) d 8.29 (bs,
1H), 7.84e7.66 (m,15H), 5.02 (bs, 2H), 4.61e4.53 (m, 2H), 3.99e3.86
(m, 2H), 3.69 (dd, J¼ 9.28, 5.18 Hz, 1H), 3.31e3.24 (m, 1H), 3.25 (s,
3H), 2.44e2.32 (m, 2H), 2.21e2.13 (m, 1H), 1.66e1.55 (m, 2H), 1.35
(s, 3H), 1.29 (s, 3H), 1.15 (s, 3H). 13C NMR (100MHz, CDCl3) d 144.5
(bs), 135.2 (d, J¼ 3.0 Hz), 133.6 (d, J¼ 10.1 Hz), 130.6 (d, J¼ 12.6 Hz),
125.5 (bs), 117.7 (d, J¼ 86.4 Hz), 101.3, 77.7, 71.8, 64.3, 49.0 (d,
J¼ 19.5 Hz), 48.5, 39.9, 34.5, 27.3, 23.3 (d, J¼ 2.4 Hz), 22.6, 19.8 (d,
J¼ 53.4 Hz), 19.1. HPLC-LRMS (ESI) m/z 574.2 [M Br]þ,




Promastigote forms of L. donovani reference strain (MHOM/NP/
02/BPK282/0cl4), L. infantum reference strain (MHOM/TN/80/IPT1),
L. major reference strain (MHOM/SU/73/5-ASKH) and L. tropica
reference strain (MHOM/SU/74/K27) were cultured at 26 C in
HOMEM (Gibco Thermo Fisher Scientific Inc., Waltham, USA) with
20% foetal bovine serum (FBS, EuroClone SpA, Milan, Italy) and 1%
penicillin-streptomycin (EuroClone SpA).
4.2.2. Cell cultures
Vero cells (kidney of African green monkey epithelial cell line)
were cultured at 37 C in MEM medium with 10% FBS (EuroClone
SpA), 1% penicillin-streptomycin (EuroClone SpA), 1% levoglut-
amine (EuroClone SpA). THP-1 cells (human leukemia monocytic
cell line) were cultured at 37 C in RPMI-1640 (EuroClone SpA)
liquid medium supplemented with 10% FBS (EuroClone SpA), 1%
levoglutamine (EuroClone SpA), 50 mM Mercaptoethanol (Gibco),
1% penicillin-streptomycin.
4.2.3. Promastigote growth inhibition assay
The late log/stationary phase of promastigotes was diluted in
complete HOMEM medium at 106 parasites/mL in 96-well plates
and the tested compounds were added at a range concentration of
40 mMe1.6 mM. Cells were incubated at 26 C for 72 h. The anti-
leishmanial drug Amphotericin B was employed as standard drug(positive control). Each experiment was carried out in duplicate. To
estimate the concentration at which the compounds caused 50%
inhibition of growth (IC50), the AlamarBlue assay was employed
(Life Technologies, Thermo Fisher Scientific Inc., Waltham, USA).
The AlamarBlue assay includes a colorimetric growth indicator
based on detection of metabolic activity. Specifically, the system
incorporates an oxidation-reduction (REDOX) indicator that fluo-
resces and changes color in response to chemical reduction of
growth medium resulting from cell growth. This method monitors
the reducing environment of proliferating cells; the cell permeable
resazurin is added (non-fluorescent form, blue color) and, upon
entering cells, is reduced to resorufin (fluorescent form, red color)
as a result of cellular metabolic activity. Evaluation was performed
after adding 20 mL of AlamarBlue to the cell cultures and incubating
at 26 C. The reducing environment was evaluated after 24 h by
absorbance measurement at the Multiskan Ascent Plate Reader
(Thermo Fisher Scientific Inc.) at 550 nm and 630 nm.
4.2.4. Anti-amastigote assay
Human acute monocytic leukemia cell line (THP1) were infected
with L. donovani promastigotes for the assessment of the activity of
the selected compounds against the amastigote form of Leishmania
parasite. THP1 cells were put in a 96-well plate (105 cells/mL) in
complete RPMI-1640 medium and PMA (0.1 mM, Cayman Chemical
Company, Ann Arbor, Michigan, USA) was added to obtain cells
adherence. Cells were incubated at 37 C in a 5% CO2 incubator.
After 48 h, themediumwas replacedwith freshmedium containing
stationary phase promastigotes that were then phagocytized by
THP-1 cells and transformed into amastigotes. After 24 h of incu-
bation, endoperoxides were added, the plates were incubated at
37 C in a 5% CO2 incubator for 72 h. After incubation, wells were
washed, fixed with methanol and stained with Giemsa. Stained
cells were visualized by using a Nikon Eclipse E200 light micro-
scope (Nikon, Tokyo, Japan). The infectivity index (% of infected
macrophages x average number of amastigotes per macrophage)
was defined by counting at least 100 THP1 cells in duplicate
cultures.
4.2.5. Cytotoxicity test
Mammalian kidney epithelial cells (Vero cell line) were seeded
(105/mL) with complete MEM medium in 96-well plates and
incubated with endoperoxides. After 72 h of incubation, 20 mL of
AlamarBlue reagent was added to each well and further incubated
at 37 C for 24 h. Reduction of resazurin to resorufin was evaluated
after 24 h by absorbance measurement at the Multiskan Ascent
Plate Reader (Thermo Fisher Scientific Inc.,) at 550 nm and 630 nm.
Each experiment was performed in duplicate. The selectivity index
(SI) for each compound was determined as the ratio between
cytotoxicity (CC50) in Vero cells and activity (IC50) against Leish-
mania promastigotes.
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